Pharmacists in Oklahoma City, Oklahoma
738 Pharmacists found in Oklahoma City
Marianne Shimanek Ratliff, DPH
Pharmacist
8 Sw 89th St Ste 200, Oklahoma City, OK 73139
405-761-2762 405-561-5960
Marjan P. Fardadfard, PHARM.D, CGP
Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
4149 Highline Blvd Ste 300, Oklahoma City, OK 73108
800-940-9963
Dr. Mark L. Britton, PHARM. D.
Pharmacist - Pharmacotherapy
Variety Care Administration, 3000 N. Grand Blvd., Oklahoma City, OK 73107
405-632-6688 844-689-9671
Dr. Mark Allen Stratton, PHARM.D.
Pharmacist - Pharmacotherapy
University Of Oklahoma, College Of Pharmacy, 1110 N. Stonewall, Oklahoma City, OK 73190
405-271-6978 405-271-6430
Mark Aaron Cotton, PHARMD
Pharmacist
4500 S Shields Blvd, Oklahoma City, OK 73129
405-631-3561 405-631-7810
Mark John Sutherland, PHARM D
Pharmacist
921 Ne 13th St, Oklahoma City, OK 73104
405-270-0501 405-290-1716
Dr. Martin L Jarshaw, PHARM.D.
Pharmacist
921 Ne 13th St, 119, Oklahoma City, OK 73104
405-270-0501 405-290-1815
Dr. Mary Jane Fry, PHARM D.
Pharmacist
11101 Hefner Pointe Dr Ste 101, Oklahoma City, OK 73120
405-755-3921 405-755-3922
Dr. Mary Stauffer, PHARM.D
Pharmacist
5700 Arnold St, 72mdg/sgsap, Oklahoma City, OK 73145
405-736-2222
Mrs. Marygrace Thomas Maliel, PHARM D
Pharmacist
921 Ne 13th St, Oklahoma City, OK 73104
405-456-1000
Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.